<DOC>
	<DOCNO>NCT02759913</DOCNO>
	<brief_summary>Prospective multicenter study subject recently diagnose amyotrophic lateral sclerosis ( ALS ) another neurodegenerative disease ( include spinal cord disease , muscle disease neurological disease multiple sclerosis , multifocal motor neuropathy , myasthenia gravis spinal muscular atrophy ) currently undergo diagnostic procedure aforementioned disease . Approximately 300 subject enrol . Subjects undergo lumbar puncture ( LP ) cerebro-spinal fluid ( CSF ) collection ; blood collection serum , plasma , RNA , DNA ( optional ) ; urine collection ( optional ) ; skin biopsy ( optional ) single visit . No study treatment administer . Subjects manage treated respective physician ; choice therapy laboratory test impact study . Clinical diagnosis may confirm subject 's physician communicate study 's Principal Investigator ( PI ) schedule telephone call .</brief_summary>
	<brief_title>A Study Evaluate Performance Diagnostic Test ALS</brief_title>
	<detailed_description>ALS , also know Lou Gehrig 's disease , rapidly progressive , degenerative disease motor neuron brain spinal cord lead muscle atrophy spasticity limb bulbar muscle . Clinical presentation fatal disease include weakness , loss ambulation , oropharyngeal dysfunction , weight loss , ultimately respiratory failure . Average survival approximately 3 year symptom onset . The initial symptom similar neuropathy ( e.g. , motor neuropathy , progressive muscle atrophy , etc . ) include limb weakness lead partial total paralysis , increase difficulty speech breathing . ALS clinical diagnosis typically take 12 month symptom onset relies exclusion potential cause clinical symptom . To date FDA-approved diagnostic test ALS . Diagnostic tool accurate early diagnosis investigation . These tool would permit early intervention , also would improve clinical trial design new drug therapy . Axonal degeneration inflammation among propose pathogenic mechanism ALS ; therefore , proteins function within pathway evaluate potential biomarkers . Iron Horse Diagnostics , Inc. ( Iron Horse ) focus ALS diagnostic effort study level cytoskeletal inflammatory protein cerebrospinal fluid ( CSF ) ALS patient . Cytoskeletal protein , include neurofilament protein tau , show elevated CSF patient various neurodegenerative disease . Interestingly , level phosphorylated neurofilament heavy subunit ( pNfH ) find significantly increase CSF ALS patient compare healthy subject , Alzheimer 's disease patient disease mimic Numerous inflammatory protein , include cytokine complement protein , show altered ALS ; complement protein , include complement c3 ( C3 ) , find increase CSF ALS patient . Iron Horse evaluate CSF sample 106 subject ( 45 ALS patient , 25 disease control range neurodegenerative condition , 36 healthy controls.CSF level pNfH , tau , C3 , C reactive protein ( CRP ) measure . pNfH significantly elevate CSF ALS subject compare healthy disease control ; significant difference CRP tau . To distinguish ALS subject disease control , data cytoskeletal inflammatory pathway combine . A ratio CSF level pNfH C3 show significant difference ALS disease healthy control group . Results verify separate test set CSF sample . Overall , predictive pNfH/C3 ratio identify ALS 87.3 % sensitivity 94.6 % specificity total 71 ALS subject , 52 disease control subject , 40 healthy subject . In study , observe plasma level pNfH significantly elevate ALS subject compare healthy control ; however significant difference ALS disease control . Comparison pNfH level CSF plasma study subject reveal weak correlation plasma CSF pNfH level . The accuracy pNfH pNfH/C3 ratio ALS predictor also test Iron Horse recent prospective , blind study collaboration Northeast ALS Consortium ( NEALS ) [ unpublished data ] . CSF ( n=126 ) plasma ( n=220 ) sample collect subject 30 medical center across United States ( US ) undergo diagnostic assessment neurodegenerative condition recently diagnose ALS . Accuracy predict ALS diagnosis 93 % CSF pNfH/C3 ratio 82 % pNfH plasma level . The prospective study propose concept test sensitivity , specificity , overall accuracy pNfH pNfH/C3 ratio ALS predictor separate sample set . CSF match plasma sample collect 6 neurodegenerative clinic 300 subject recently diagnose ALS another similar neurologic disease currently undergo diagnostic procedure .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>To eligible participate study , candidate must meet following eligibility criterion Screening Visit : 1 . Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( PHI ) accordance national local subject privacy regulation . 2 . Aged 21 80 year old , inclusive . 3 . Must meet one following : Recent diagnosis sporadic familial ALS ( within 18 month first visit ALS symptom ) accord World Federation Neurology El Escorial criterion ( revise accord Airlie House Conference 1998 [ Brooks 1999 ] ) . Recent diagnosis neuromuscular disease ALS ( within 12 month first visit neurologic symptom ) . Undergoing diagnostic procedure neuromuscular disease . 4 . Willingness medical ability comply schedule visit , LP CSF collection , laboratory test , study procedure . Candidates exclude study entry follow exclusion criterion exist Screening Visit : 1 . Any contraindication LP , include limited : Platelet count &lt; 100,000/ÂµL . History bleed disorder . Use platelet antiaggregant anticoagulant drug , include limited clopidogrel , dipyridamole , ticlopidine , warfarin . Use aspirin prophylactic dose 75325 mg r less acceptable . History intolerance LP procedure . Evidence topical skin infection LP site . Prior spinal fusion surgery spinal surgery LP site . 2 . If undergoing skin biopsy , evidence topical skin infection biopsy site . 3 . History allergy adverse reaction local anesthetic use study . 4 . History traumatic central nervous system injury stroke . 5 . History chronic liver renal failure . 6 . Requirement artificial respiration , include tracheostomy use bilevel positive airway pressure ( BiPAP ) therapy . 7 . Female subject pregnant currently breastfeed . 8 . Current enrollment investigational drug , medical device , disease study . 9 . Other unspecified reason , opinion Investigator Iron Horse , make subject unsuitable enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>neuromuscular disease</keyword>
</DOC>